Sign up
LXEO

Lexeo Therapeutics, Inc. Common Stock (NASDAQ: LXEO)

Healthcare · Biotechnology

$2.95+0.10 (+3.33%)

Last close · Nov 18, 2026 · NASDAQ USD

Set alert

The Quantellect read. LXEO rose 3.33% in the Nov 18 session to $2.95. The borrow fee is 0.92%. Six active firms cover the stock as of Nov 19, 2026; six active firms with targets average $15.83 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

MomentumNeutral

RSI (14) 48.0 (overbought above 70, oversold below 30)

Trend—

—

Short interest33.3% of float

FINRA settlement Oct 30, 2026

LXEO price chart

Price $2.95 · As of Nov 18, 2026, 3:59 PM ET

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open
$2.80Nov 18, 2026 session
Previous close
$2.86Nov 17, 2026 close
Day range
$2.76 – $3.09Nov 18, 2026 session
52-week range—
Volume
1.76MNov 18, 2026 session
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

LXEO · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 18
Squeeze59Watch—
How the scores work →

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

Buy

1Strong Buy
5Buy
0Neutral
0Sell
0Strong Sell

Based on 6 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$9.00
Average$15.83
High$25.00

As of Nov 19, 2026 across 6 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q3 2026−$0.32−$0.43—
Q2 2026−$0.30−$0.30—
Q1 2026—−$0.25—
Annual 2025−$0.86−$1.86—
Q3 2025—−$0.33—
Q2 2025—−$0.60—
Q1 2025—−$0.99—
Annual 2024−$0.72−$3.09—

Smart-money activity

— · Smart-money activity not available

All smart-money activity →

News and press releases

All LXEO news →

Company profile

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a

CEO
Mr. R. Nolan Townsend M.B.A.
Headquarters
New York, NY, United States
Employees
63
IPO date
Nov 3, 2023
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.